Cassava Sciences Inks Consulting Pact With Ex-CEO Remi Barbier
BioNTech Raised to Buy at Jefferies on New Cancer Drug
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
Small-cap Stocks Have Climbed Recently. Here Are the Ones Most Poised for Further Upside
Centessa Pharmaceuticals Analyst Ratings
Alphabet To $200? Here Are 10 Top Analyst Forecasts For Monday
Summit Therapeutics Analyst Ratings
Summit Therapeutics Says Ivonescimab Data Were Presented At 2024 ESMO Annual Meeting, Including Two Presentations And One Poster Featuring Updated Ivonescimab Data In Advanced Triple-negative Breast Cancer, Recurrent/Metastatic Head And Neck Squamous...
The increase within the year reached 1123%! The cooperation between Chinese and American pharmaceutical companies defeated the "global pharmaceutical king", and the CEO said straightforwardly, "We are on the right side".
Summit Pharmaceuticals has surpassed the global drug king pembrolizumab from China's pharmaceutical company Akeso with its new drug Yervoy (PD-1/VEGF bispecific antibody) in a head-to-head clinical trial.
Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?
Trending Stocks This Week as Market Bounces Back From Selloff
Summit Boosts Instil, BioNTech as Lead Drug Beats Merck's Keytruda
Summit Therapeutics Shares Are Trading Higher After the Company on Thursday Announced It Raised $235 Million in Net Proceeds.
Here's How Much $100 Invested In Summit Therapeutics 5 Years Ago Would Be Worth Today
Goldman Sachs Maintains Buy on Viridian Therapeutics, Raises Price Target to $31
Signet Jewelers Posts Better-Than-Expected Earnings, Joins NETGEAR, Lovesac And Other Big Stocks Moving Higher On Thursday
New Additions to Roth MKM's ADR Portfolio for September
Why Summit Therapeutics (SMMT) Stock Is Rising Today
Summit Therapeutics Jumps 4%, Raises $235M
Centessa Pharmaceuticals Announces $150M Proposed Public Offering Of American Depositary Shares